The Benefits of Wearable AI in Post-Discharge Management of AMI Patients
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorRenJi Hospital
About this trial
Myocardial infarction (MI) remains a major threat to human health. Although interventional treatment techniques have advanced rapidly, many patients still experience major adverse cardiovascular events (MACE) and require hospital readmission after discharge. Artificial intelligence (AI) based on wearable device data has shown great potential in the diagnosis and management of cardiovascular diseases.
This study aims to explore the clinical value of wearable device-based data analysis and AI-driven risk stratification models in post-discharge management of acute myocardial infarction (AMI) patients.
Eligibility criteria
Qualifiers
Adults aged 18 to 75 years.
Confirmed diagnosis of acute myocardial infarction (AMI), including both ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI).
Underwent successful percutaneous coronary intervention (PCI) during index hospitalization.
Hemodynamically stable at the time of hospital discharge.
Disqualifiers
Planned staged or elective PCI or any coronary revascularization scheduled within 3 months after discharge.
Unable to tolerate or contraindicated for wearing metal or electronic monitoring devices.
Pregnant or breastfeeding women.
Residence in an area without stable network connectivity or inability to use a smartphone for data upload and communication.
Trial design
Treatments tested in this trial
- Optimized Integrated Management Based on AI-Guided Wearable Data
Treatment groups
200 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov